Recent Transactions

13-Nov-24
Pending
$12.1 billion
United States flag
Target: 

Blue Owl Technology Finance Corp. II (“OTF II”)

United States flag
Acquiror: 
Blue Owl Technology Finance Corp. (“OTF”)

Advised and provided a fairness opinion to the Special Committee of the Independent Directors of OTF II, a specialty finance company focused on originating and making loans to, and making debt and equity investment in, technology related companies, specifically software, based primarily in the US, on its merger with OTF 

30-Sep-24
Undisclosed
United States flag
Target: 

Golub Capital LLC

Japan flag
Acquiror: 
Mizuho Bank, Ltd.

Advising Mizuho Bank, Ltd., the banking arm of Mizuho Financial Group, Inc., on its purchase of a passive, non-voting minority stake in Golub Capital’s management companies

01-Jul-24
Undisclosed
United States flag
Target: 

Medical Review Institute of America

United States flag
Acquiror: 
Parthenon Capital

Advised Medical Review Institute of America, a portfolio company of Summit Partners and a leading provider of outsourced utilization management and clinical review solutions to payors, on its strategic growth investment from Parthenon Capital

08-May-24
$800 million
United States flag
Target: 

U.S. Acute Care Solutions

flag not available

Advised U.S. Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on the refinancing of its senior secured notes

27-Sep-23
Undisclosed
United States flag
Target: 

Slayback Pharma LLC

United States flag
Acquiror: 
Azurity Pharmaceuticals

Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products

01-Jun-23
Pending
Undisclosed
United States flag
Target: 

Interest in Joint Venture with CarepathRx Health System Solutions

United States flag
Acquiror: 
The Cigna Group

Advising Cigna on its investment in CarepathRx Health System Solutions, under Evernorth, Cigna’s health services subsidiary

10-Feb-23
Pending
$415 million
United States flag
Target: 

Gaming Services Division of Global Payments

United States flag
Acquiror: 
Parthenon Capital

Advising Parthenon Capital, a financial services & technology focused private equity firm, on its acquisition of Global Payment’s Gaming Services Division, a leading provider of on-site and digital payment processing services to companies in the gaming industry, for $415mm

23-Jan-23
Pending
$200 million
United Kingdom flag
Target: 

Clinigen Ltd’s Proleukin

United States flag
Acquiror: 
Iovance Biotherapeutics

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies

30-Dec-22
$153 million
United States flag
Target: 

Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products

Australia flag
Acquiror: 
Mayne Pharma

Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma

19-Aug-22
$2.2 billion
United States flag
Target: 

GI Alliance

United States flag
Acquiror: 
Apollo Hybrid Value Fund

Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital

28-Mar-22
Pending
~$1.4 billion
United Kingdom flag
Target: 

Theramex

United States flag
Acquiror: 
Carlyle and PAI Partners

Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners

28-Mar-22
Pending
$105 million
United Kingdom flag
Target: 

Acacia Pharma Group plc

United States flag
Acquiror: 
Eagle Pharmaceuticals, Inc.

Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise

01-Feb-22
Undisclosed
United States flag
Target: 

Alteon Health

United States flag
Acquiror: 
U.S. Acute Care Solutions

Advised Alteon Health, a portfolio company of New Mountain Capital and national physician-led provider of emergency medicine, hospitalist medicine and post-acute care services, on its sale to U.S. Acute Care Solutions

28-Jan-22
Undisclosed
United States flag
Target: 

Akorn Pharmaceuticals Portfolio of Branded Ophthalmic Products

France flag
Acquiror: 
Laboratoires Théa SAS

Advised Akorn Pharmaceuticals, a specialty pharmaceuticals manufacturer and marketer, on the divestiture of its portfolio of branded ophthalmic products to Laboratoires Théa SAS

20-Jan-22
Pending
Undisclosed
United States flag
Target: 

GrowFlow Corp.

United States flag
Acquiror: 
Dama Financial

Advising Dama Financial, the nation’s largest provider of access to banking and payment solutions for the cannabis industry, on its acquisition of GrowFlow Corp, a leading business management and compliance software platform for cannabis retailers, cultivators, processors, and distributors

29-Sep-21
~$1.1 billion
Colombia flag
Target: 

Procaps Group

United States flag
Acquiror: 
Union Acquisition Corp. II (NASDAQ: LATN)

Advised Procaps Group, a leading integrated international healthcare and pharmaceutical company, on its successful business combination with Union Acquisition Corp II (NASDAQ: LATN), a LatAm-focused special purpose acquisition company. Procaps Group now trades on the Nasdaq Global Market under the ticker symbol "PROC"

20-Sep-21
Undisclosed
Spain flag
Target: 

Faes Farma, flagship product Bilastine

United States flag
Acquiror: 
Hikma Specialty USA INC

Advised Faes Farma in the signing of a long-term license agreement for its flagship product Bilastine with Hikma Specialty USA INC, a subsidiary of Hikma Pharmaceuticals PLC, for the United States of America

11-Sep-21
Pending
Undisclosed
United States flag
Target: 

California-based Property and Casualty insurance subsidiary of Covéa

United States flag
Acquiror: 
Porch Group

Advising Covéa, a leading French mutual insurance company, on the sale of its wholly owned subsidiary, CSE Insurance group, to Porch Group

09-Sep-21
Undisclosed
United States flag
Target: 

Quicken

United States flag
Acquiror: 
Aquiline Capital Partners

Advised Aquiline Capital Partners on its acquisition of Quicken, the best-selling personal finance software in the U.S., from H.I.G. Capital

05-Jul-21
Undisclosed
United States flag
Target: 

American Stock Transfer & Trust Company

United States flag
Acquiror: 
Siris Capital Group LLC

Advised Siris Capital, a private equity firm focused on the technology sector, on its acquisition of American Stock Transfer & Trust Company, a leading technology-enabled full service professional services firm

01-Jun-21
Undisclosed
United States flag
Target: 

VEP Healthcare

United States flag
Acquiror: 
U.S. Acute Care Solutions

Advised VEP Healthcare, a leading, physician-owned provider of clinical management services in emergent and inpatient settings in the United States, on its merger with U.S. Acute Care Solutions

27-May-21
$1.4 billion
United Kingdom flag
Target: 

Equiniti Group PLC

United States flag
Acquiror: 
Siris Capital Group LLC

Advised Siris Capital, a private equity firm focused on the technology sector, on its recommended 180p cash offer for Equiniti Group PLC, a technology-led services and payments specialist

07-May-21
N/A
United States flag
Target: 

MindPath Care Centers

United States flag
Acquiror: 
Community Psychiatry

Advised Community Psychiatry, a leading provider of outpatient behavioral health services with a focus on high-quality clinically-driven care, on its acquisition of MindPath Care Centers, deepening its national presence to more than 350 providers across the US

26-Feb-21
$2.0 billion
United States flag
Target: 

MDLIVE

United States flag
Acquiror: 
Cigna

Advising Cigna on the acquisition of MDLIVE, a virtual care delivery platform, by Evernorth, Cigna’s health services portfolio

19-Feb-21
$33 million
U.S.A., U.K. flags
Target: 

Acacia Pharma Group plc

flag not available
Acquiror: 
N/A

Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share

Pages

show all